Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials

Author： Ederhy Stephane

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.30, Iss.2, 2012-04, pp. : 611-615

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lower toxicity with targeted anticancer agents in phase I trials

Reactions Weekly, Vol. 1, Iss. 1416, 2012-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Low skeletal muscle is associated with toxicity in patients included in phase I trials

By Cousin Sophie Hollebecque A. Koscielny S. Mir O. Varga A. Baracos V. Soria J. Antoun S.

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 382-387

Springer Publishing Company

Access to resources Recommend Favorite

Publication biases and phase II trials investigating anticancer targeted therapies

By Penel Nicolas Adenis Antoine

Investigational New Drugs, Vol. 27, Iss. 3, 2009-06 ,pp. : 287-288

Springer Publishing Company

Access to resources Recommend Favorite

Ethical Issues in Phase I Cancer Clinical Trials

By Peppercorn Jeffrey

International Journal of Pharmaceutical Medicine, Vol. 20, Iss. 4, 2006-01 ,pp. : 233-242

Adis International

Access to resources Recommend Favorite

Lancet issues call for phase I trials

Inpharma, Vol. 1, Iss. 1554, 2006-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite